HONG KONG – Following a priority review, Astrazeneca plc won approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Tagrisso (osimertinib). The drug is now greenlighted as a first-line treatment in patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).
HONG KONG – Following a priority review, Astrazeneca plc won approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its Tagrisso (osimertinib). The drug is now greenlighted as a first-line treatment in patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).
HONG KONG – Roche Holding AG was granted a rapid approval from the China National Drug Administration (CNDA) for Alecensa (alectinib). The drug was greenlighted as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small-cell lung cancer (NSCLC).
HONG KONG – Roche Holding AG was granted a rapid approval from the China National Drug Administration (CNDA) for Alecensa (alectinib). The drug was greenlighted as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small-cell lung cancer (NSCLC).
HONG KONG – Anges Inc. has signed a co-development agreement with Vasomune Therapeutics Inc. for the global development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization.
HONG KONG – Anges Inc. has signed a co-development agreement with Vasomune Therapeutics Inc. for the global development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization.
HONG KONG – Israel's Can-Fite Biopharma Ltd. has received a first payment of $2 million from CMS Medical Venture Investment Ltd., as part of a recent $72 million development, registration and marketing agreement for the exclusive rights of Can-Fite's lead drug candidates in greater China, an area that includes Hong Kong, Macao and Taiwan.
HONG KONG – China's I-Mab Biopharma Co. Ltd. entered a strategic partnering agreement with ABL Bio Inc., of South Korea. I-Mab will out-license its bispecific antibody (BsAb) for an undisclosed target to ABL Bio for about $100 million.
HONG KONG – Singaporean biotech startup Dotbio Pte. Ltd. launched this week with seed capital of $2.3 million. The new player on the biotech scene is focused on the development of immuno-oncology drugs based on humanized domain antibodies.
